Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor-targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Pancreatic and esophageal cancer cohorts.

被引：0

作者：

Ulahannan, Susanna Varkey

Johnson, Melissa Lynne

Weiss, Mia C.

Vandross, Andrae L.

Vidal-Cardenas, Sofia Luz

Syed, Mustafa

Tolcher, Anthony W.

机构：

[1] Univ Okahoma, Hlth Sci Ctr, Oklahoma City, OK USA

[2] Sarah Cannon Res Inst, Nashville, TN USA

[3] Washington Univ, Sch Med St Louis, St Louis, MO USA

[4] NEXT Oncol, Austin, TX USA

[5] Exelixis Inc, Alameda, CA USA

[6] NEXT Oncol, San Antonio, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期

关键词：

283-237-6846-271-2644; 3282-3306-2666-3910; 283-324; 298-145-222-184-4809-5347; 283-237-267; 261-566-9263; 283-2494; 4; 2; 14; 1;

D O I：

10.1200/JCO.2024.42.3_suppl.TPS421

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：TPS421 / TPS421

页数：1

共 32 条

[21] YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase I study
Zhao, H.
Ma, Y.
Meng, X.
Wu, L.
Fan, Y.
Zheng, Y.
Liu, Z.
Ji, Y.
Lv, D.
Luo, S.
Sommerhalder, D.
Fu, S.
Huang, Y.
Yang, Y.
Fang, W.
Zhao, Y.
Wang, Y.
Chin, S.
Xue, T.
Zhang, L.
ANNALS OF ONCOLOGY, 2024, 35 : S485 - S485
[22] Phase 1, open-label, dose-escalation and expansion study of ABBV-399, an antibody drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors.
Strickler, John H.
Nemunaitis, John J.
Weekes, Colin D.
Ramanathan, Ramesh K.
Angevin, Eric
Morgensztern, Daniel
Heist, Rebecca Suk
Bauer, Todd Michael
Kaminker, Patrick
Fan, Xiaolin
Siggelkow, Sara
Wong, Shekman
Reilly, Edward B.
Afar, Daniel E.
Naumovski, Louie
Kelly, Karen
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[23] PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients (pts) with advanced solid tumors: Results of a phase I dose escalation and expansion study.
Sachdev, Jasgit C.
Maitland, Michael L.
Sharma, Manish
Moreno, Victor
Boni, Valentina
Kummar, Shivaani
Stringer-Reasor, Erica Michelle
Forero-Torres, Andres
Lakhani, Nehal J.
Gibson, Brenda
Xuan, Dawei
Joh, Tenshang
Powell, Eric L.
Jackson-Fisher, Amy
Xin, Xiaohua
Tolcher, Anthony W.
Calvo, Emiliano
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[24] Safety and efficacy of IBI343 (anti-claudin18.2 antibody-drug conjugate) in patients with advanced pancreatic ductal adenocarcinoma or biliary tract cancer: Preliminary results from a phase 1 study
Yu, Xianjun
Zhang, Jian
Tazbirkova, Andrea
Yang, Jianwei
Yue, Jinbo
Sun, Yuping
Pan, Yueyin
Sun, Meili
Qin, Yanru
Shen, Lin
Song, Rongfeng
Ruan, Jian
Zhou, Aiping
Mou, Yiping
Liu, Zimin
Liu, Zhenyang
Zhang, Yongchang
Morris, Michelle
Aghmesheh, Morteza
Zhou, Hui
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[25] Phase 1 study of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors.
Borghaei, Hossein
O'Malley, David M.
Seward, Shelly Marie
Bauer, Todd Michael
Perez, Raymond P.
Oza, Amit M.
Jeong, Woondong
Michenzie, Mary F.
Kirby, Maurice William
Chandorkar, Gurudatt
Ruiz-Soto, Rodrigo
Birrer, Michael J.
Moore, Kathleen N.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[26] Dose escalation and expansion results from the phase I study of F0024, a trophoblast cell-surface antigen 2 (TROP2) antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.
Du, Yiqun
Meng, Yanchun
Wang, Jingfen
Wang, Ying
Wu, Fan
Chen, Yu
Chen, Lilin
Qing, Lihua
Qiao, Yaya
Liu, Kezhen
Sun, Wenyi
Li, Xiaowen
Zhang, Jian
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[27] A Phase 1/2 Study of the CD56-targeting Antibody-Drug Conjugate, Lorvotuzumab Mertansine (LM, IMGN901), in Combination with Carboplatin/Etoposide in Patients with Solid Tumors including Small Cell Lung Cancer (SCLC)
Spigel, D. R.
Bendell, J. C.
Mita, A. C.
Argiris, A.
Kurkjian, C.
Hann, C. L.
Segota, E.
Johnson, D. S.
Schindler, J.
Gutierrez, M. E.
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S278 - S278
[28] BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with Locally Advanced or Metastatic Breast Cancer and other Solid Tumor: Results from a phase 1 study
Wu, Jiong
Zhang, Jian
Du, Yiqun
Zou, Wen
Ding, Muran
Yang, Hui
Xiao, Sa
Wang, Hongwei
Zhu, Hai
Olivo, Martin
Zhu, Yi
CANCER RESEARCH, 2024, 84 (09)
[29] SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001)
Hollebecque, Antoine
Lopez, Juanita Suzanne
Piha-Paul, Sarina A.
Dowlati, Afshin
Patnaik, Amita
Galvao, Vladimir
Bockorny, Bruno
Sehgal, Kartik
Kingsley, Ed
Sanborn, Rachel E.
Perez, Cesar Augusto
Peters, Solange
Yan, Mingjin
Nazarenko, Natalya N.
Calvo, Emiliano
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[30] A phase 1, first-in-human study of CUSP06, a cadherin-6 (CDH6) -directed antibody-drug conjugate, in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
Spira, Alexander I.
Lee, Elizabeth Katherine
O'Cearbhaill, Roisin Eilish
LoRusso, Patricia
Falchook, Gerald Steven
Patel, Manish R.
Richardson, Debra L.
Lu, Nicole Covino Wei
Marreddy, Priya
Farrington, Daphne L.
Wheler, Jennifer J.
Slosberg, Eric Daniel
Subbiah, Vivek
Meric-Bernstam, Funda
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 →